| Patient | Pablo Neruda |
|---|---|
| Date of birth | 1959-07-12 |
| Identifiers | MRN HR-ML051-SYN; SSN (made up) 000-51-2976 |
| Document date | 2026-06-01 |
| Author | Marisol Fairweather-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
The patient attends this visit for new patient with four months of urinary symptoms and six weeks of right hip and low back pain: examination, PSA and baseline tests, pain control, the staging and biopsy plan, and medical oncology referral. [S]
PSA: 46.8 ng/mL (high); Total testosterone: 468 ng/dL; Hemoglobin: 13.6 g/dL; White cell count: 6.4 10*3/uL; Platelets: 248 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Glucose: 104 mg/dL (high); Creatinine: 0.96 mg/dL; eGFR (CKD-EPI 2021): 87 mL/min/1.73 m²; Calcium: 9.6 mg/dL; ALT: 22 U/L; AST: 24 U/L; Alkaline phosphatase: 168 U/L (high); Albumin: 4.1 g/dL; LDH: 208 U/L; Hemoglobin A1c: 5.9% (high); Total cholesterol: 214 mg/dL (high); HDL cholesterol: 46 mg/dL; LDL cholesterol: 140 mg/dL (high); Triglycerides: 140 mg/dL; 25-hydroxyvitamin D: 22 ng/mL (low); PHQ-9: 6; IPSS total (0 to 35): 17; Pain, 0 to 10: 6. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-01 | Body height | 178 | cm | S |
| 2026-06-01 | Body weight | 92.4 | kg | S |
| 2026-06-01 | Body mass index (BMI) [Ratio] | 29.2 | kg/m2 | S |
| 2026-06-01 | Systolic blood pressure | 146 | mm[Hg] | S |
| 2026-06-01 | Diastolic blood pressure | 88 | mm[Hg] | S |
| 2026-06-01 | Heart rate | 76 | /min | S |
| 2026-06-01 | Respiratory rate | 14 | /min | S |
| 2026-06-01 | Body temperature | 36.7 | Cel | S |
| 2026-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-01 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 46.8 | ng/mL | <=4 ng/mL | High | S |
| 2026-06-01 | Testosterone [Mass/volume] in Serum or Plasma | 468 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Normal | S |
| 2026-06-01 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-06-01 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-01 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-01 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-01 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 2026-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-01 | Calcium [Mass/volume] in Serum or Plasma | 9.6 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-06-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 2026-06-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-48 U/L | Normal | S |
| 2026-06-01 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 168 | U/L | 40-129 U/L | High | S |
| 2026-06-01 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-06-01 | Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma | 208 | U/L | 135-225 U/L | Normal | S |
| 2026-06-01 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9 | % | <=5.6% | High | S |
| 2026-06-01 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 2026-06-01 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-06-01 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 140 | mg/dL | <=129 mg/dL | High | S |
| 2026-06-01 | Triglyceride [Mass/volume] in Serum or Plasma | 140 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-06-01 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-06-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-06-01 | International Prostate Symptom Score [IPSS] | 17 | {score} | S | ||
| 2026-06-01 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-04-06 to 2026-07-13 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain | Two tablets up to three times daily as needed | Oral route | 2026-06-01 to 2026-09-14 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed | active | confirmed | R97.20 | S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer. |
| Essential hypertension for five years, on amlodipine | active | confirmed | I10 | S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure. |
| Prediabetes (hemoglobin A1c 5.9%) | active | confirmed | R73.03 | S — Synthetic metabolic finding at intake, relevant to androgen deprivation. |